Scott T. Rottinghaus insider trades: Enanta Pharmaceuticals (ENTA) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Scott reports to the SEC
Open-market buys and sales
4 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Dec 5, 2025 | ENTA | ↓ Sell | 798 | $14.23 | $11K | Direct | Dec 5, 2025 (0d) |
| Dec 6, 2024 | ENTA | ↓ Sell | 866 | $8.06 | $7K | Direct | Dec 10, 2024 (4d) |
| Jul 15, 2024 | ENTA | ↓ Sell | 11,945 | $15.97 | $191K | Direct | Jul 15, 2024 (0d) |
| Dec 5, 2023 | ENTA | ↓ Sell | 534 | $9.63 | $5K | Direct | Dec 6, 2023 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other ENTA insiders
Open-market trades in the last 12 months
About Scott T. Rottinghaus's insider trades
Scott T. Rottinghaus is Chief Medical Officer at Enanta Pharmaceuticals (ENTA). Since Dec 5, 2023, Scott has reported no open-market purchases and 4 sales worth $214K on SEC Form 4. In the last 12 months: 1 sale ($11K).
Their filings also include grants and awards (7 filings), shares withheld for taxes (5 filings), option exercises (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ENTA insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.